SciFi Futures
← Concepts
Biotech & Medicine

Whole-body rejuvenation treatment

A repeatable clinical procedure that repairs accumulated age damage throughout the body, returning an old person to youthful function and extending lifespan by centuries.

In shortWhole-body rejuvenation treatment, from Mars Trilogy (Red Mars, Green Mars, Blue Mars) (Kim Stanley Robinson, 1992), Methuselah's Children (Robert A. Heinlein, 1958) and Hyperion (Dan Simmons, 1989), is at technology readiness level 3 of 9 (experimental proof of concept) at its weakest link. Held back by Causal mechanisms of aging. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $23B–80B.

Vlad Taneev and Ursula Kohl develop the gerontological treatment at Acheron - a whole-body genomic and protein repair course, repeated every decade, that keeps the First Hundred alive into their 200s while causing sudden quick-decline deaths.
Mars Trilogy (Red Mars, Green Mars, Blue Mars) by Kim Stanley Robinson, 1992Set in 2045Tight19 years left to climb 5 TRL steps (3.8 yrs/step)
The Howard Families' long lifespans, and later a blood-and-tissue rejuvenation procedure developed aboard the New Frontiers, restore youth to already-old members.
Methuselah's Children by Robert A. Heinlein, 1958Set in 2136On track110 years left to climb 5 TRL steps (22.0 yrs/step)
Poulsen treatments extend the lives of the wealthy by centuries; the poet Martin Silenus has had enough of them to have lived for centuries.
Hyperion by Dan Simmons, 1989Set in 2851On track825 years left to climb 5 TRL steps (165.0 yrs/step)

Closest todayPartial epigenetic reprogramming entered first-in-human testing in 2026 in one eye of glaucoma patients; senolytics and rapamycin trials target single diseases, and no intervention has been shown to extend healthy human lifespan.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • criticalCausal mechanisms of agingbottleneck
    A treatment that repairs age damage requires knowing which damage is causal and a biomarker that shows the repair worked
    • No validated surrogate biomarker of biological age, so any whole-body rejuvenation claim needs decade-long outcome trials
    • Hallmarks of aging are correlated; interventions cannot yet be attributed to a specific causal node
    • Mouse lifespan results have repeatedly failed to transfer to longer-lived species
    TRL 3
  • Resetting cellular age without losing cell identity is the closest real mechanism to the depicted treatment
    ✕3 blockers›
    • Dose and duration window is narrow - too much OSK expression causes loss of cell identity and teratoma risk
    • Doxycycline-gated expression gives coarse control over how far each cell is rewound
    • No delivery route demonstrated for simultaneous reprogramming of many tissues in one body
    TRL 4
    • Deciding how far to rewind a cell requires knowing which epigenetic changes are causal
      TRL 3
    • Factors must reach the target tissue and be switchable in vivo
      ✕3 blockers›
      • Systemic LNPs partition to liver and spleen; tropism for kidney, bone marrow and solid tumors is weak
      • Anti-AAV immunity excludes many patients and blocks redosing
      • Payload size caps (about 4.7 kb for AAV) exclude large multi-gene constructs
      TRL 6
      • Receptor-specific capsids and shuttle peptides are the main route to non-liver tropism
        ✕1 blocker›
        • Designing catalysis and conformational dynamics
        TRL 6
  • Rejuvenation must reach every tissue, not just liver and eye
    TRL 6
  • The depicted treatment repairs accumulated genomic damage in situ
    ✕2 blockers›
    • Delivery to tissues beyond liver
    • Long-term off-target safety
    TRL 6
  • Organs too damaged to repair have to be replaced for a centuries-long lifespan
    ✕4 blockers›
    • Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
    • Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
    • Cell demand of 10^10-10^11 per organ exceeds current manufacturing
    • Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
    TRL 4
    • Without a capillary network, tissue thicker than a few hundred microns dies
      ✕3 blockers›
      • Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
      • Engineered endothelium is thrombogenic, so perfused constructs clot
      • No method guides anastomosis of a construct's vasculature to host vessels at scale
      TRL 3
    • Banked-cell organs are not patient-matched, so acceptance must be engineered
      ✕3 blockers›
      • Chronic antibody-mediated rejection proceeds even under current immunosuppression
      • Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
      • No assay predicts which recipients can be safely weaned off drugs
      TRL 5
    • One organ needs 10^10-10^11 clinical-grade cells of several types
      ✕3 blockers›
      • Genomic instability and drift accumulate over the expansion needed for 10^11 cells
      • Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
      • Cost per cell at current media and reagent prices makes a printed organ unaffordable
      TRL 6

Who could unlock it

  • Across several requirements:
  • Life Biosciences 2
  • Altos Labs 2
Causal mechanisms of agingTRL 3bottleneck
  • Life BiosciencesStartup
    Partial epigenetic reprogramming (OSK); started the first human trial of ER-100 in optic neuropathies in Q1 2026 and raised an $80M Series D in April 2026
  • Retro BiosciencesStartup
    Dosed its first clinical candidate RTR242 in 2025 and raised a round at a $1.8B pre-money valuation in 2026, across cell therapy, reprogramming and protein design
  • Altos LabsStartup
    Launched in 2022 with roughly $3B to pursue cellular rejuvenation programming, the largest private bet on reprogramming-based aging biology
  • Steve HorvathResearcher, Altos Labs
    Built the epigenetic clocks (2013 onward) that are the leading candidate biological-age measures; moved from UCLA to Altos Labs in 2022
Partial epigenetic reprogramming of adult tissueTRL 4
  • Life BiosciencesStartup
    Received FDA clearance in January 2026 and dosed the first patient in its ER-100 OSK Phase 1 (NCT07290244); closed an 80 million dollar Series D in April 2026
  • Altos LabsStartup
    Launched in 2022 with 3 billion dollars to pursue reprogramming-based rejuvenation; its 2024 and 2025 papers extended lifespan in progeria mice and reversed mesenchymal drift
  • Juan Carlos Izpisua BelmonteResearcher, Altos Labs
    Pioneered cyclic in vivo partial reprogramming and reported Cdkn2a-promoter-gated OSK extending mouse lifespan without increased tumour occurrence (2024)
  • David SinclairResearcher, Harvard Medical School
    His OSK optic-nerve rejuvenation work is the basis of Life Biosciences ER-100, the first partial-reprogramming therapy dosed in humans
Tissue-targeted nucleic acid deliveryTRL 6
  • Daniel SiegwartResearcher, UT Southwestern Medical Center
    Invented selective organ targeting lipid nanoparticles that redirect mRNA to lung and spleen, and in 2025 traced the effect to protein-corona composition
  • Dyno TherapeuticsStartup
    Designs AAV capsids with machine learning; licensed a CNS capsid to Roche in January 2025 and had a skeletal-muscle capsid optioned by Astellas
  • Capsida BiotherapeuticsStartup
    Engineers tissue-selective capsids paired with its own manufacturing, aimed specifically at targets outside the liver
  • Tessera TherapeuticsStartup
    Its proprietary lipid nanoparticles delivered Gene Writers to haematopoietic stem cells and T cells in primates with editing durable to about 15 months (2025)
Precise in vivo gene editingTRL 6
  • Intellia TherapeuticsCompany
    Its Phase 3 HAELO trial of lonvo-z (NTLA-2002) in hereditary angioedema met the primary and all key secondary endpoints in April 2026, the first Phase 3 data for any in vivo gene-editing therapy
  • David LiuResearcher, Broad Institute of MIT and Harvard
    Invented base and prime editing; his lab designed the base editor used for baby KJ in 2025 and is extending prime editing to disease-agnostic suppressor-tRNA approaches
  • Kiran MusunuruResearcher, University of Pennsylvania and Children's Hospital of Philadelphia
    Led the first patient-specific in vivo base-editing therapy, an LNP-delivered editor given to an infant with CPS1 deficiency (NEJM, May 2025), and is building umbrella platforms for urea-cycle disorders and PKU
  • NIH Somatic Cell Genome Editing ConsortiumProgram
    NIH Common Fund program funding targeted delivery technologies, safety assays and platform clinical-trial pathways; it underwrote the preclinical work behind the KJ therapy

Beyond engineering

  • No regulatory pathway for an aging indication without a qualified surrogate endpoint
  • Distribution of a scarce life-extending treatment is the central political conflict of the Mars trilogy and would be of any real rollout
  • Pension, inheritance and population structures assume a bounded lifespan